Gastric mucosal lesion
Conditions
Interventions
Control group(P):Anesthesia induction (propofol 1.5mg/kg, Sufen 0.3ug/kg, Cisatracurium 0.2mg/kg), anesthesia maintenance (continuous infusion of propofol 4-12mg/kg/h, Remifen 0.1-0.3ug/kg/min)
Experimental Group(C):Anesthesia induction (cyclopofol 0.3mg/kg, sufen 0.3ug/kg, Cisatracurium 0.2mg/kg), anesthesia maintenance (continuous infusion of cyclopofol 0.4-2.4mg/kg/h, Remifen 0.1-0.3ug/kg
Sponsors
Mianyang 404 Hospital (The First People's Hospital Of Mianyang)
Eligibility
Sex/Gender
All
Age
65 Years to 80 Years
Inclusion criteria
Inclusion criteria: a. Patients scheduled for gastric ESD treatment; b. Male or female, aged >=65 and =18 and <=30kg/m ²; e. Be able to understand the procedures and methods of this study, be willing to sign the informed consent form and strictly abide by the protocol of this trial to complete this study.
Exclusion criteria
Exclusion criteria: A. Those with contraindications to general anesthesia or a history of anesthesia accidents in the past; b. Those who are known to be allergic to excipients in propofol injection, excipients in cyclopofol injection (soybean oil, glycerin, triglycerides, egg yolk lecithin, sodium oleate and sodium hydroxide), opioids, cisatracurium and its drug components; Contraindications of propofol; c. There is a history or evidence of the following increased sedation/anesthesia risk before screening/baseline period: 1) Cardiovascular history: Severe arrhythmia, heart failure, Adams-stokes syndrome, unstable angina pectoris, third-degree atrioventricular block; 2) History of respiratory system: Those who have developed acute respiratory tract infection within one week and have obvious symptoms such as fever, wheezing, nasal congestion and coughing; 3) History of cerebrovascular diseases: Those with a history of craniocerebral injury, possible convulsions, myoclonus, intracranial hypertension, cerebral aneurysms, or cerebrovascular accidents; Schizophrenia, mania, mental confusion, long-term use of psychotropic drugs, history of cognitive dysfunction, etc. 4) Gastrointestinal history: Gastrointestinal retention, active bleeding, and conditions that may lead to reflux and aspiration; d. Subjects who the researchers consider to have any other factors that make them unsuitable for participating in this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of perioperative bradycardia; | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of perioperative hypotension;The quality of patient recovery;Incidence of injection pain;Postoperative adverse reactions such as nausea and vomiting;The duration for which the patient leaves the resuscitation room after the operation; | — |
Countries
China
Contacts
Public ContactPang Xiaoyi
Mianyang 404 Hospital (The First People's Hospital Of Mianyang)
Outcome results
None listed